Indication
Moderate persistent asthma
Moderate persistent asthma is a clinical severity classification of chronic asthma, an inflammatory disorder of the lower respiratory tract affecting both pediatric and adult populations. Read more about Moderate persistent asthma
6 drugs 3 manufacturers
Drugs that treat it
Common Moderate persistent asthma therapies.
DUPIXENT (dupilumab)
XOLAIR (omalizumab)
DUPIXENT PEN (dupilumab)
DUPIXENT SYRINGE (dupilumab)
OMLYCLO (omalizumab-igec)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonModerate persistent asthma is a clinical severity classification of chronic asthma, an inflammatory disorder of the lower respiratory tract affecting both pediatric and adult populations.
Pathophysiologically characterized by airway hyperresponsiveness, chronic bronchial wall inflammation, and reversible airflow obstruction, it presents with daily symptoms such as wheezing, dyspnea, chest tightness, and cough.
Clinically, this stage is defined by daily rescue inhaler use, nighttime awakenings occurring more than once per week, and some degree of limitation in normal daily activity.
Objective pulmonary function testing typically demonstrates a forced expiratory volume in one second (FEV1) or peak expiratory flow between 60% and 80% of predicted values, alongside a reduced FEV1/FVC ratio.
- nih.gov
Moderate persistent asthma is a clinical severity classification of chronic asthma, an inflammatory disorder of the lower respiratory tract affecting both pediatric and adult populations Pathophysiologically characterized by airway hyperresponsiveness, chronic bronchial wall inflammation, and reversible airflow obstruction, it presents with daily symptoms such as wheezing, dyspnea, chest tightness, and cough
- cdc.gov
Moderate persistent asthma is a clinical severity classification of chronic asthma, an inflammatory disorder of the lower respiratory tract affecting both pediatric and adult populations
- cdc.gov
Pathophysiologically characterized by airway hyperresponsiveness, chronic bronchial wall inflammation, and reversible airflow obstruction, it presents with daily symptoms such as wheezing, dyspnea, chest tightness, and cough
- healthline.com
Clinically, this stage is defined by daily rescue inhaler use, nighttime awakenings occurring more than once per week, and some degree of limitation in normal daily activity
- alberta.ca
Clinically, this stage is defined by daily rescue inhaler use, nighttime awakenings occurring more than once per week, and some degree of limitation in normal daily activity Objective pulmonary function testing typically demonstrates a forced expiratory volume in one second (FEV1) or peak expiratory flow between 60% and 80% of predicted values, alongside a reduced FEV1/FVC ratio
Personalize your experience
Follow Moderate persistent asthma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.